Know what protections and rights you have as a study participant.
This right is absolute. You are never locked into a clinical trial. You can stop at any time, for any reason. You do not need permission. You do not need a medical excuse. You can say "I am done" and walk away. This protection is guaranteed under federal regulation 45 CFR 46 (the Common Rule), which governs all federally funded human subjects research in the United States.
Your medical care continues after withdrawal. If you were receiving standard medical treatment before the trial, you can go back to that. Leaving a trial has no legal or financial consequences for your access to care, your insurance, or your relationship with non-trial physicians.
Some trials have safety-related taper schedules for withdrawal, especially for drugs that should not be stopped abruptly. The trial team will discuss this with you when you withdraw, but the team cannot force you to continue. You can request immediate discontinuation, accept a tapered withdrawal, or decline both. The decision is yours.
Before you enroll, the research team must explain the trial to you in plain English. They must describe the risks, the benefits, your rights, what the protocol requires, how data will be used, and what alternatives exist outside the trial. They provide written consent forms. You have the right to take time to read them, ask questions, take them home, and think about your decision before signing.
Signing consent means you understand what you are agreeing to. If you do not understand something, the team must explain it again. The consent form is not a gotcha. It is your protected right to fully understand what you are agreeing to before participating in research.
You can withdraw your consent at any time after signing. The signature does not lock you in. Your right to withdraw is restated in the consent form itself, and the trial team is required to honor that withdrawal without retaliation.
The 2018 revisions to the Common Rule strengthened informed consent requirements. Consent forms must now include a concise summary of the key information at the very beginning, written so a reasonable person could decide whether to participate. If a consent form does not include this summary or is hard to read, you can ask for a clearer version, and the IRB requires the trial team to provide one.
You have the right to be informed of any new findings during a clinical trial that might affect your willingness to continue participating. This is called the duty to disclose, and it is required by 45 CFR 46.116(b)(5). New findings can include safety signals from other participants, updated risk estimates, changes to the protocol, or information about a competing therapy that has become available.
When new safety information emerges, the IRB reviews whether the consent form needs to be revised and whether existing participants need to be reconsented. Reconsent is the formal process where the trial team re-explains the trial with the new information and asks you to sign an updated consent form. You can decline reconsent and withdraw, with no consequences for your medical care.
You also have the right to request your individual study results when the trial ends, and many sponsors now provide them by default. Aggregate trial results must be posted to ClinicalTrials.gov within 12 months of trial completion under FDA Amendments Act Section 801 requirements. This is a public record that anyone can search.
Every legitimate clinical trial in the United States is reviewed and approved by an Institutional Review Board (IRB) before it starts. An IRB is an independent committee of doctors, scientists, ethicists, statisticians, and community members who review the trial to ensure it is ethical and safe. They review the informed consent forms, the protocol, and the qualifications of the research team. They ensure that the risks are justified by the potential benefits.
IRBs also monitor the trial while it is running. If problems come up, the IRB can require protocol changes, suspend enrollment, or stop the trial entirely. Each IRB-approved trial is subject to continuing review at least annually, and more often for higher-risk studies.
You can contact the IRB directly if you have concerns about how a trial is being conducted. The IRB contact information is required to appear on every informed consent form. If you do not feel comfortable raising a concern with the trial team, the IRB is the independent body that exists to receive participant complaints.
IRBs in the United States are regulated by the FDA and the Office for Human Research Protections (OHRP). Most academic medical centers have their own IRB, while many trial sponsors use a central commercial IRB (such as Advarra or WCG) to coordinate review across multiple sites. Both types must follow the same federal regulations.
Large clinical trials and most trials of high-risk interventions have a Data Safety Monitoring Board (DSMB), also called a Data Monitoring Committee (DMC). This is an independent group of clinicians and statisticians who review accumulating trial data on a pre-specified schedule. The DSMB has access to unblinded outcome data that the front-line trial team cannot see during the trial.
The DSMB has three primary actions available. They can recommend stopping the trial early for efficacy if the active drug is working so well that continuing the comparator arm would be unethical. They can recommend stopping for safety if the drug is causing unexpected harm. They can recommend protocol modifications, such as adjusting the dose, changing inclusion criteria, or adding new safety assessments.
You will not interact with the DSMB directly, and the DSMB does not interact with individual participants. Their role is population-level oversight, designed to protect future enrollees and to catch trends that no individual trial team would see. Knowing a DSMB is monitoring your trial is one of the strongest assurances of independent safety oversight available in clinical research.
The informed consent form must disclose what compensation, if any, is available if you are injured by participating in a trial. Federal regulations do not require sponsors to provide compensation for injury, but many large industry-sponsored trials do carry trial liability insurance, and most academic centers have their own injury compensation policies.
The standard wording on a consent form will state whether the sponsor will pay for medical care related to a trial-caused injury, whether they will compensate for lost wages or long-term disability, and what your options are if compensation is denied. If the consent form is silent or vague on this point, ask the coordinator before signing. Get the answer in writing.
If you experience a serious adverse event during a trial, document it in writing, request copies of all medical records, and contact the IRB if you feel the trial team is not being responsive. You can also report concerns to FDA MedWatch or to OHRP. Many disease-specific advocacy organizations have legal aid networks for participants pursuing trial injury claims.
Your trial data is protected under the Health Insurance Portability and Accountability Act (HIPAA) and additional research-specific privacy regulations. Researchers cannot share your protected health information with third parties without your specific authorization. The HIPAA authorization for research participation is typically a separate form from the informed consent form, and you have the right to revoke it at any time.
Trial data is de-identified for analysis and publication. If results are published in medical journals, your name and identifying information are not included. Aggregate results posted to ClinicalTrials.gov also exclude personal identifiers. Some trials may use a Certificate of Confidentiality issued by the NIH, which provides additional legal protection against forced disclosure of research data, even by court subpoena in many circumstances.
Ask the coordinator about data use before enrolling. How long will they keep your data? Who can access it? Can you request that your data be destroyed if you withdraw? Some trials retain data indefinitely for long-term follow-up; others allow withdrawal of identifiable data after the trial ends. The HIPAA authorization form should specify the answer.
Federal regulations provide additional protections for participants who are considered vulnerable due to limited capacity to give voluntary informed consent. Subpart B of 45 CFR 46 covers pregnant women, fetuses, and neonates. Subpart C covers prisoners. Subpart D covers children. Each subpart adds specific consent and ethics requirements beyond the general Common Rule.
For children, parental permission is required, and children old enough to understand (typically age 7 and up) must provide assent. The IRB reviews whether the trial offers direct benefit to the child and how risks compare to those a child would face in everyday life. Higher-risk pediatric trials require federal-level review under 45 CFR 46.407.
For adults with limited decision-making capacity (such as severe cognitive impairment or active psychosis), a Legally Authorized Representative (LAR) can provide consent on the participant's behalf, but the participant must still be given the opportunity to assent or dissent in a manner consistent with their abilities. State laws govern who qualifies as an LAR.
Trials that enroll prisoners, pregnant women in research not directly benefiting them, or other specifically vulnerable groups must include the protections detailed in the relevant subpart of 45 CFR 46. The IRB reviews these added protections and can require sponsor modifications before approval.
If you have concerns about how a trial is being conducted, you have multiple channels for raising them. Each channel addresses a different type of concern, and you can use more than one if appropriate.
The first contact for most concerns is the trial site IRB. Their phone number is on the informed consent form, and they receive participant complaints regularly. The IRB can investigate concerns about consent, conduct, or unexpected risks at the site level.
For concerns about a specific drug or device safety issue, FDA MedWatch is the federal mechanism for reporting adverse events. Reports can be filed online by patients, family members, or providers. The FDA reviews MedWatch data for safety signals across all trials and approved products.
For concerns about how human subjects research is conducted at a federally funded site, the Office for Human Research Protections (OHRP) accepts complaints under 45 CFR 46. OHRP can investigate institutions and require corrective action.
For concerns about discrimination, financial exploitation, or other patterns of misconduct, your state attorney general office, your state medical board, or a patient advocacy organization in your disease area can be appropriate next steps. Document everything in writing, keep copies of all correspondence, and seek legal advice if you believe you have been seriously harmed.
Clinical trial participants have the right to informed consent, the right to withdraw at any time without penalty, the right to be told about new information that could affect their participation, the right to privacy and HIPAA protection of their health data, the right to know about Institutional Review Board oversight of the trial, and the right to file complaints if they believe the trial is being conducted improperly. These rights are protected under federal regulation 45 CFR 46 and FDA Good Clinical Practice guidance.
Yes, you can withdraw from a clinical trial at any time, for any reason, without losing access to standard medical care. This right is absolute and is required by federal regulation 45 CFR 46. The informed consent form must explicitly state your right to withdraw. Some trials use a tapered withdrawal schedule for drugs that should not be stopped abruptly, but you cannot be forced to continue if you decide to leave.
Informed consent in a clinical trial is the process by which a potential participant learns the key facts of a study (purpose, procedures, risks, benefits, alternatives, costs, and rights) and decides whether to participate. The consent must be given freely, in a language the participant understands, and after they have had time to ask questions and consider their options. Federal regulations require informed consent for all human subjects research, with specific elements detailed in 45 CFR 46.116.
An Institutional Review Board (IRB) is an independent committee that reviews and oversees clinical trials to protect human research subjects. The IRB reviews the protocol, the informed consent form, and the qualifications of the research team before approving a trial. The IRB also monitors the trial during conduct and can require changes, suspend enrollment, or stop the trial if problems arise. Every U.S. clinical trial requires IRB approval before it can begin.
A Data Safety Monitoring Board (DSMB), also called a Data Monitoring Committee, is an independent group of clinicians and statisticians who review accumulating clinical trial data while the trial is running. The DSMB has access to unblinded outcome data that the trial team cannot see during the trial. They can recommend stopping the trial early for efficacy, stopping for safety, or modifying the protocol. DSMBs are required for most large trials and high-risk studies.
Yes, your health information in a clinical trial is protected under HIPAA and additional research privacy regulations. Researchers cannot share your protected health information with third parties without your specific written authorization. Trial data is de-identified for analysis and publication. Some trials use NIH-issued Certificates of Confidentiality to provide additional legal protection against forced disclosure even under court subpoena.
If you are injured in a clinical trial, the informed consent form must explain what compensation is available. Federal law does not require sponsors to provide compensation, but many do carry trial liability insurance. The sponsor typically covers medical care directly related to a trial-caused injury, but coverage of lost wages, long-term disability, or pain and suffering varies. Ask the coordinator before signing, and document any adverse event in writing if one occurs.
To file a complaint about a clinical trial, contact the trial site Institutional Review Board first (their phone number is on the informed consent form). For drug or device safety concerns, file a report with FDA MedWatch. For concerns about how human subjects research is conducted at a federally funded institution, contact the Office for Human Research Protections (OHRP). Document everything in writing and keep copies of all correspondence.
Children in clinical trials are protected under Subpart D of 45 CFR 46, which adds requirements beyond the general Common Rule. Parental permission is required, and children old enough to understand (typically age 7 and up) must provide assent. The IRB reviews the balance of risks and direct benefit to the child. Higher-risk pediatric trials require additional federal review under 45 CFR 46.407, and the FDA Pediatric Research Equity Act requires pediatric assessments for many new drugs.